Li Kang Biomedical Co Ltd Asset Resilience Ratio
Li Kang Biomedical Co Ltd asset resilience ratio. Li Kang Biomedical Co Ltd (6242) has an Asset Resilience Ratio of 12.99% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 6242 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Li Kang Biomedical Co Ltd (2002–2025)
Asset resilience ratio of Li Kang Biomedical Co Ltd from 2002 to 2025. This chart shows how Li Kang Biomedical Co Ltd's Asset Resilience Ratio has changed over time. Read 6242 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Li Kang Biomedical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Li Kang Biomedical Co Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$142.03 Million | 12.99% |
| Total Liquid Assets | NT$142.03 Million | 12.99% |
Asset Resilience Insights
- Moderate Liquidity: Li Kang Biomedical Co Ltd has 12.99% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Li Kang Biomedical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Li Kang Biomedical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royal Caribbean Cruises Ltd
NYSE:RCL |
Travel Services | 2.26% |
|
Norwegian Cruise Line Holdings Ltd
NYSE:NCLH |
Travel Services | 0.00% |
|
Rainbow Tours SA
WAR:RBW |
Travel Services | 0.22% |
|
Corporate Travel Management Ltd
AU:CTD |
Travel Services | 0.70% |
|
Aviation Links Ltd
TA:AVIA |
Travel Services | 11.28% |
|
Flight Centre Travel Group Ltd
AU:FLT |
Travel Services | 0.41% |
|
WEB Travel Group Ltd
AU:WEB |
Travel Services | 1.41% |
|
Helloworld Travel Ltd
AU:HLO |
Travel Services | 5.39% |
Li Kang Biomedical Co Ltd Asset Resilience Ratio by Year (2002–2025)
Li Kang Biomedical Co Ltd asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Li Kang Biomedical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.48% | NT$147.30 Million ≈ $4.64 Million |
NT$1.09 Billion ≈ $34.44 Million |
-24.13pp |
| 2024-12-31 | 37.61% | NT$389.45 Million ≈ $12.27 Million |
NT$1.04 Billion ≈ $32.63 Million |
+14.73pp |
| 2023-12-31 | 22.88% | NT$189.18 Million ≈ $5.96 Million |
NT$827.00 Million ≈ $26.06 Million |
+3.80pp |
| 2022-12-31 | 19.08% | NT$131.42 Million ≈ $4.14 Million |
NT$688.84 Million ≈ $21.70 Million |
+7.00pp |
| 2021-12-31 | 12.08% | NT$74.39 Million ≈ $2.34 Million |
NT$616.07 Million ≈ $19.41 Million |
-6.92pp |
| 2020-12-31 | 19.00% | NT$122.50 Million ≈ $3.86 Million |
NT$644.77 Million ≈ $20.31 Million |
+10.72pp |
| 2019-12-31 | 8.28% | NT$51.84 Million ≈ $1.63 Million |
NT$626.44 Million ≈ $19.74 Million |
+3.71pp |
| 2013-12-31 | 4.56% | NT$5.10 Million ≈ $160.68K |
NT$111.79 Million ≈ $3.52 Million |
+2.13pp |
| 2009-12-31 | 2.43% | NT$6.15 Million ≈ $193.76K |
NT$252.83 Million ≈ $7.97 Million |
-1.75pp |
| 2008-12-31 | 4.18% | NT$18.34 Million ≈ $577.78K |
NT$438.89 Million ≈ $13.83 Million |
+2.75pp |
| 2007-12-31 | 1.43% | NT$10.01 Million ≈ $315.37K |
NT$701.86 Million ≈ $22.11 Million |
-0.50pp |
| 2006-12-31 | 1.92% | NT$14.56 Million ≈ $458.66K |
NT$757.63 Million ≈ $23.87 Million |
-0.42pp |
| 2005-12-31 | 2.34% | NT$18.54 Million ≈ $584.17K |
NT$791.11 Million ≈ $24.92 Million |
-0.01pp |
| 2004-12-31 | 2.35% | NT$18.05 Million ≈ $568.55K |
NT$766.35 Million ≈ $24.14 Million |
-0.48pp |
| 2003-12-31 | 2.83% | NT$21.82 Million ≈ $687.48K |
NT$770.15 Million ≈ $24.26 Million |
+1.37pp |
| 2002-12-31 | 1.47% | NT$11.24 Million ≈ $354.00K |
NT$765.96 Million ≈ $24.13 Million |
-- |
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. produces and sells pharmaceuticals, beauty products, and health food. It offers Chinese and Western medicines, nutritional supplements, beauty and skincare products, and daily necessities products. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was fou… Read more